PRELUDE THERAPEUTICS I

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

31 May 2023 08:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Pricing of Public Offering

18 May 2023 07:00:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Launch of Proposed Public Offering

17 May 2023 16:08:22 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

08 May 2023 08:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

27 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

11 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

15 Mar 2023 08:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

15 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Prelude Therapeutics To Participate in Barclays Global Healthcare Conference

01 Mar 2023 08:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

09 Feb 2023 09:05:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

14 Nov 2022 08:00:02 By Nasdaq GlobeNewswire

Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

18 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences

06 Sep 2022 08:00:02 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

09 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

10 May 2022 08:00:02 By Nasdaq GlobeNewswire

Prelude Therapeutics Reports Full Year 2021 Financial Results

16 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

11 Mar 2022 08:00:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

09 Mar 2022 08:05:00 By Nasdaq GlobeNewswire

Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer

09 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

11 Feb 2022 07:00:00 By Nasdaq GlobeNewswire